HMG (Menopur / Pergonal)
Prescription fertility hormone mixture that athletes who have used steroids try in order to restart their own hormone production; banned in sport.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is HMG (Menopur / Pergonal)?
HMG (human menopausal gonadotropin) is a hormone mixture purified from the urine of postmenopausal women, containing FSH and LH in roughly equal proportions. In men, the former supports sperm production and the latter stimulates testosterone production. As a prescription medicine (Menopur) it is used in fertility treatment; its predecessor, Pergonal, was withdrawn worldwide around 2005 because of a theoretical risk of infection.
After long, strong hormonal suppression, steroid users try it to restart their own production, because unlike HCG, which only mimics LH, it replaces both hormones. Estrogen levels may rise (breast growth, water retention, mood swings), and acne, headache, reactions at the injection site, allergy and, rarely, a blood clot can occur. It cannot be used with hormone-dependent tumors, and it does not work if the testicle is faulty to begin with (for example in Klinefelter syndrome). It is banned year-round in competitive sport. In men, only a few smaller studies have been done, mostly in patients with hormone deficiency.
Mechanism
Mixture of follicle-stimulating and luteinizing hormone from urine
Half-life
FSH ~24-36 h / LH ~20 h (mixed component decay)
Onset
Test rise 5-10 days, spermatogenesis restart 4-8 weeks
Legal status
EMA Rx Menopur (Ferring 2002), USA FDA Rx Menopur (2005), WADA S2 (banned)
No anecdote collected yet.
Data console
Lab data
Zheng Y, Bai HZ, Zhao GC . Comparison of outcomes between pulsatile gonadotropin releasing hormone and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism.. Reprod Biol Endocrinol.
Schaison G, Young J, Pholsena M, Edery M, Touraine P, Lahlou N . Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism.. J Clin Endocrinol Metab.
Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. . Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol. 2002;147(5):617-24..
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Estrogen rebound: FSH+LH stimulation raises endogenous testosterone and secondarily E2, at higher doses (>150 IU EOD) causing gynecomastia, water retention and mood swings.
- Injection-site reactions (SC/IM): pain, redness, swelling, itching, rarely haematoma or sterile abscess at the injection site.
- Hypersensitivity and allergic reactions to the urine-derived protein: urticaria, rash, rarely severe systemic (anaphylactic) reactions.
- Headache, fatigue, abdominal discomfort and bloating, nausea – common, dose-dependent, usually mild gonadotropin side effects.
- Testicular tenderness and transient enlargement from the dual Leydig+Sertoli stimulus; risk of receptor downregulation with prolonged (>6 weeks) monotherapy.
- Acne and oily skin, mood irritability secondary to rising endogenous androgen levels.
- Thromboembolic risk (rare): the classic gonadotropin class warning notes possible venous/arterial thrombosis, especially with congenital or acquired thrombophilia.
Contraindications · 7
- Known hypersensitivity to HMG, menotropins or any excipient (urine-derived protein sensitization).
- Hormone-dependent tumors or their suspicion: testicular, prostate, pituitary or hypothalamic tumor – gonadotropin stimulation may promote their progression.
- Infertility of a cause on which HMG is ineffective (Klinefelter syndrome, Y-chromosome deletion, primary testicular failure) – no therapeutic benefit.
- Untreated or poorly controlled endocrine disorder (thyroid, adrenal dysfunction, hyperprolactinemia) – must be corrected first.
- Pre-pubertal males and childhood – not indicated in this user context.
- Active thromboembolic disease or severe thrombophilia – relative contraindication due to the gonadotropin class thrombosis risk, requires close monitoring.
- Concurrent exogenous TRT (chronic testosterone) – Leydig cells are suppressed, HMG stimulation is ineffective and pointless in this context.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Comparison of outcomes between pulsatile gonadotropin releasing hormone and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism.
Zheng Y, Bai HZ, Zhao GC
Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism.
Schaison G, Young J, Pholsena M, Edery M, Touraine P, Lahlou N
Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone
Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E.
Telegram
Have a question about HMG (Menopur / Pergonal)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


